|
|
 |
|
Viewing report
|
|
|
|
Acorda Therapeutics, Inc.: SWOT Analysis & Company Profile
Business Review, Sep 2010, Pages: 23
Business Review’s Acorda Therapeutics, Inc. contains a company overview, key facts, locations and subsidiaries, news and events as well as a SWOT analysis of the company.
Summary
This SWOT Analysis company profile is a crucial resource for industry executives and anyone looking to quickly understand the key information concerning Acorda Therapeutics, Inc.’s business.
Business Review’s “Acorda Therapeutics, Inc. SWOT Analysis & Company Profile” reports utilize a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Business Review strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about (Acorda Therapeutics, Inc.) for business intelligence requirements
- Studies and presents Acorda Therapeutics, Inc.’s strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
- The profile contains business operations, the company history, major products and services, prospects, key competitors, structure and key employees, locations and subsidiaries.
Reasons To Buy
- Quickly enhance your understanding of the company.
- Obtain details and analysis of the market and competitors as well as internal and external factors which could impact the industry.
- Increase business/sales activities by understanding your competitors’ businesses better.
- Recognize potential partnerships and suppliers.
- Obtain yearly profitability figures
Key Highlights
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in identification, development and commercialization of therapies for spinal cord injury, multiple sclerosis and other froms of nervous system disorders. The company’s markets a wide range of tablets such as Ampyra (dalfampridine) extended release tablets, to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets which are the short-acting drugs approved for the management of spasticity. Further, the company has three preclinical programs namely, Chondriotinase, Remyelinating antibodies and Neuregulins focused on novel approaches to repair damaged components of the CNS. The company is headquartered in New York, the US.
|
|
|
|
